Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

“…Our data also show that anagrelide can be considered a safe drug, despite some cardiovascular adverse effects that can usually be managed by dose reductions. 35 For personal use only. on May 10, 2018.…”

Tratamiento del paciente con trombocitemia esencial

“…Otra estrategia es dividir la dosis aumentando la frecuencia de las tomas (cada 6-8 h). Adicionalmente, pueden administrarse betabloqueantes como el atenolol (25-50 mg/día), el metoprolol de acció n retardada (25-50 mg/día) y el bisoprolol (2,5-5 mg/día) 41,42 .…”

Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine

“…Except from lowering the platelets number (in the unclear mechanism) this molecule inhibits also phosphodiesterase III, thus exerts positive inotropic and chronotropic effects and may induce vasospam directly on the epicardial coronary arteries. Both can contribute to the onset of cardiovascular adverse events [4][5][6]. The most common are tachycardia and irregular pulse, however, rare cases of acute myocardial infarction were also reported [5].…”

“…Both can contribute to the onset of cardiovascular adverse events [4][5][6]. The most common are tachycardia and irregular pulse, however, rare cases of acute myocardial infarction were also reported [5]. Recently, a case…”

“…Both can contribute to the onset of cardiovascular adverse events [4][5][6]. The most common are tachycardia and irregular pulse, however, rare cases of acute myocardial infarction were also reported [5]. Recently, a case of a 75-year-old woman who developed an atypical, mid-ventricular TC while on anagrelide therapy (1.5 mg/day for six months) was reported [4,6].…”